Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials
- 8 July 2024
- journal article
- review article
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 42 (5) , 492-502
Abstract
Introduction We aimed to comprehensively compile placebo-controlled trials on the efficacy and safety of romosozumab (210 mg, subcutaneously, once monthly) in postmenopausal women and men with osteoporosis. Materials and methods PubMed, Google Scholar, and ClinicalTrials.gov were searched for relevant placebo-controlled trials (as of January 1, 2024). Percent change in bone mineral density (BMD), falls, fractures, and adverse events (AEs) after drug administration were collected. Risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Results Six trials (7990 patients; follow-up period, 6–12 months) were included. Compared with placebo, romosozumab significantly increased lumbar spine BMD (MD = 12.69; 95% CI 11.10–14.29), total hip BMD (MD = 4.42; 95% CI 3.03–5.80), and femoral neck BMD (MD = 3.99; 95% CI 2.42–5.57) at 12 months. Romosozumab significantly decreased falls (RR = 0.80; 95% CI 0.68–0.93) and major osteoporotic fractures (RR = 0.37; 95% CI 0.25–0.54), but increased injection-site reactions (RR = 1.83; 95% CI 1.46–2.30) within 12 months. No significant differences were observed in other AEs (including cardiovascular AEs) within 12 months. Conclusion Romosozumab treatment resulted in a significant BMD gain, reduced falls and major osteoporotic fractures. It was generally well-tolerated, including the cardiovascular aspects. However, clinicians should consider the occurrence of minor AEs (e.g., injection-site reactions).Keywords
This publication has 47 references indexed in Scilit:
- Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials (CDM‐J)Pharmacoepidemiology and Drug Safety, 2023
- Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney DiseaseJournal of Bone and Mineral Research, 2022
- Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized TrialsJournal of Bone and Mineral Research, 2020
- Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumabOsteoporosis International, 2019
- Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older WomenJournal of Bone and Mineral Research, 2019
- Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group StudyJournal of Bone and Mineral Research, 2018
- Imminent risk of fracture after fractureOsteoporosis International, 2016
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With OsteoporosisJAMA, 2016
- Changes in thigh muscle volume predict bone mineral density response to lifestyle therapy in frail, obese older adultsOsteoporosis International, 2013
- Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare eventsStatistics in Medicine, 2006